Medical University of South Carolina — Biomedical Watch V2

Traitements19programmes

Essais9liés

Publications7liées

SourceDBlocale

Traitements

19

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
Accelerated intermittent theta-burst stimulation (iTBS) rTMS to right superior parietal lobule (rSPL)The goal of this study is to determine the whether a short-term, high-dose form of non-invasive brain stimulation (intermittent theta burst stimulation; iTBS) is a promising and safe treatment for mild cognitive impairment in Parkinson's disease (PD-MCI).	Parkinson	Non applicable	À vérifier	United States	À vérifier
High Dose Mesenchymal Stem Cells (MSCs)The purpose of this study is to evaluate the efficacy and safety of mesenchymal stem cells (MSCs) obtained from umbilical cords for the treatment of adults with systemic lupus erythematosus (SLE). The goal of this study is to determine if patients receiving an MSC infusion plus standard of care respond better than patients receiving placebo infusion plus standard of care.	Lupus	Phase 2	Thérapie cellulaire	United States	À vérifier
Imaging Biomarkers of FOG Response to DBSFor this study, the investigators are recruiting 54 individuals with Parkinson's Disease and Freezing of Gait (FOG) who are planning to undergo Deep Brain Stimulation (DBS). The objective of this study is to better understand the FOG response to DBS. Prior to DBS, participants will undergo an MRI scan, behavioral assessment related to walking, a cognitive evaluation, and assessment of other Parkinson's disease symptoms. Following DBS, participants will repeat these assessments at multiple timepoints over the period of one year. Overall, participants will complete a total of 7 visits over a period of approximately 1 year.	Parkinson	Phase 4	Traitement symptomatique	United States	À vérifier
Low Dose Mesenchymal Stem Cells (MSCs)The purpose of this study is to evaluate the safety of mesenchymal stromal cells (MSCs) obtained from umbilical cords for the treatment of adults with active systemic lupus erythematosus (SLE).	Lupus	Phase 2	Thérapie cellulaire	United States	À vérifier
MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System (Active)Apathy is a common set of symptoms seen in many people following a stroke. Apathy occurs when a person has lost motivation, becomes withdrawn, and stops doing things that used to be important to them. Apathy has a large negative impact on a person's quality of life, and can also have a large impact the people who take care of them. There are currently no FDA-approved treatments to help with apathy, and other services like therapy may be difficult to access for people who have had a stroke. To address this problem, investigators are conducting a study to find out if a form of treatment called repetitive transcranial magnetic stimulation (rTMS) can be safe and helpful for people struggling with apathy after a stroke. This study will apply a new form of rTMS which can be delivered quickly to a part of the brain called the medial prefrontal cortex (mPFC). This study will help establish whether this treatment is safe, comfortable, and effective for people with apathy after a stroke, and will help researchers develop new forms of treatment.	Accident vasculaire cérébral	Phase 1/2	Traitement symptomatique	United States	À vérifier
MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System (Sham)Apathy is a common set of symptoms seen in many people following a stroke. Apathy occurs when a person has lost motivation, becomes withdrawn, and stops doing things that used to be important to them. Apathy has a large negative impact on a person's quality of life, and can also have a large impact the people who take care of them. There are currently no FDA-approved treatments to help with apathy, and other services like therapy may be difficult to access for people who have had a stroke. To address this problem, investigators are conducting a study to find out if a form of treatment called repetitive transcranial magnetic stimulation (rTMS) can be safe and helpful for people struggling with apathy after a stroke. This study will apply a new form of rTMS which can be delivered quickly to a part of the brain called the medial prefrontal cortex (mPFC). This study will help establish whether this treatment is safe, comfortable, and effective for people with apathy after a stroke, and will help researchers develop new forms of treatment.	Accident vasculaire cérébral	Phase 1/2	Traitement symptomatique	United States	À vérifier
Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION)This single-arm Phase II trial evaluates whether omission of postoperative radiotherapy is feasible and oncologically safe in select patients with HPV-associated oropharyngeal squamous cell carcinoma (HPV-OPSCC). Eligible patients undergo transoral robotic surgery (TORS) and are observed without adjuvant radiation if they demonstrate low or intermediate pathological risk features and have negative circulating tumor HPV DNA (ctHPVDNA) two weeks post-operatively. Patients are followed with standard clinical surveillance combined with serial ctHPVDNA testing (NavDx®) to facilitate early detection of recurrence and prompt salvage therapy as needed.	Cancer	Phase 2	À vérifier	United States	À vérifier
Remote Transcutaneous Auricular Vagal Nerve Stimulation Paired with Task-Specific TrainingEarly evidence suggests the benefits of post-stroke motor rehabilitation may be enhanced by applying electrical stimulation to the ear. This study aims to test the new approach of pairing ear stimulation with motor rehabilitation in the home setting in stroke survivors with upper limb motor function deficits.	Accident vasculaire cérébral	Non applicable	À vérifier	United States	À vérifier
SLEIGH — Systemic Lupus Erythematosus in Gullah HealthSystemic lupus erythematosus (SLE) is an autoimmune disease characterized by the production of autoantibodies, multiple organ involvement, and diverse clinical symptoms and immunologic manifestations. African Americans are at a disproportionately higher risk of developing SLE, develop SLE at an earlier age, and have increased morbidity and mortality compared with European Americans. Our central study hypothesis is that there are specific genetic factors that interact with environmental exposures leading to the development of SLE. The African American Gullah population from the Sea Islands of South Carolina and Georgia are unique in their genetic homogeneity with minimal non-African genetic admixture, making them an ideal cohort to address questions of environmental and genetic influence on the development and progression of SLE.	Lupus	À vérifier	Ralentissement de la progression + Traitement symptomatique	United States	À vérifier
Transauricular Vagus Nerve StimulationThe purpose of this study is to explore whether a non-invasive form of ear stimulation called transcutaneous auricular vagus nerve stimulation (taVNS) can manage symptoms in patients with autism spectrum disorder (ASD). Additionally, this study also uses magnetic resonance imaging (MRI) to capture images of participants' brains and apply an image processing method called INSCAPE to track brain state changes during taVNS treatment in ASD. Investigators will recruit up to 16 participants with ASD.	SEP	Non applicable	Traitement symptomatique	United States	À vérifier
Low Dose Mesenchymal Stem Cells (MSCs)The purpose of this study is to evaluate the safety of mesenchymal stromal cells (MSCs) obtained from umbilical cords for the treatment of adults with active systemic lupus erythematosus (SLE).	Lupus	Phase 1	Thérapie cellulaire	United States	À vérifier
Imaging Biomarkers of FOG Response to DBSFor this study, the investigators are recruiting 54 individuals with Parkinson's Disease and Freezing of Gait (FOG) who are planning to undergo Deep Brain Stimulation (DBS). The objective of this study is to better understand the FOG response to DBS. Prior to DBS, participants will undergo an MRI scan, behavioral assessment related to walking, a cognitive evaluation, and assessment of other Parkinson's disease symptoms. Following DBS, participants will repeat these assessments at multiple timepoints over the period of one year. Overall, participants will complete a total of 7 visits over a period of approximately 1 year.	Parkinson	Phase 4	Traitement symptomatique	United States	À vérifier
SLEIGH — Systemic Lupus Erythematosus in Gullah HealthSystemic lupus erythematosus (SLE) is an autoimmune disease characterized by the production of autoantibodies, multiple organ involvement, and diverse clinical symptoms and immunologic manifestations. African Americans are at a disproportionately higher risk of developing SLE, develop SLE at an earlier age, and have increased morbidity and mortality compared with European Americans. Our central study hypothesis is that there are specific genetic factors that interact with environmental exposures leading to the development of SLE. The African American Gullah population from the Sea Islands of South Carolina and Georgia are unique in their genetic homogeneity with minimal non-African genetic admixture, making them an ideal cohort to address questions of environmental and genetic influence on the development and progression of SLE.	Lupus	À vérifier	Ralentissement de la progression + Traitement symptomatique	United States	À vérifier
Low Dose Mesenchymal Stem Cells (MSCs)The purpose of this study is to evaluate the safety of mesenchymal stromal cells (MSCs) obtained from umbilical cords for the treatment of adults with active systemic lupus erythematosus (SLE).	Lupus	Phase 2	Thérapie cellulaire	United States	À vérifier
Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION)This single-arm Phase II trial evaluates whether omission of postoperative radiotherapy is feasible and oncologically safe in select patients with HPV-associated oropharyngeal squamous cell carcinoma (HPV-OPSCC). Eligible patients undergo transoral robotic surgery (TORS) and are observed without adjuvant radiation if they demonstrate low or intermediate pathological risk features and have negative circulating tumor HPV DNA (ctHPVDNA) two weeks post-operatively. Patients are followed with standard clinical surveillance combined with serial ctHPVDNA testing (NavDx®) to facilitate early detection of recurrence and prompt salvage therapy as needed.	Cancer	Phase 2	À vérifier	United States	À vérifier
Transauricular Vagus Nerve StimulationThe purpose of this study is to explore whether a non-invasive form of ear stimulation called transcutaneous auricular vagus nerve stimulation (taVNS) can manage symptoms in patients with autism spectrum disorder (ASD). Additionally, this study also uses magnetic resonance imaging (MRI) to capture images of participants' brains and apply an image processing method called INSCAPE to track brain state changes during taVNS treatment in ASD. Investigators will recruit up to 16 participants with ASD.	SEP	Non applicable	Traitement symptomatique	United States	À vérifier
Accelerated intermittent theta-burst stimulation (iTBS) rTMS to right superior parietal lobule (rSPL)The goal of this study is to determine the whether a short-term, high-dose form of non-invasive brain stimulation (intermittent theta burst stimulation; iTBS) is a promising and safe treatment for mild cognitive impairment in Parkinson's disease (PD-MCI).	Parkinson	Non applicable	À vérifier	United States	À vérifier
Remote Transcutaneous Auricular Vagal Nerve Stimulation Paired with Task-Specific TrainingEarly evidence suggests the benefits of post-stroke motor rehabilitation may be enhanced by applying electrical stimulation to the ear. This study aims to test the new approach of pairing ear stimulation with motor rehabilitation in the home setting in stroke survivors with upper limb motor function deficits.	Accident vasculaire cérébral	Non applicable	À vérifier	United States	À vérifier
MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System (Active)Apathy is a common set of symptoms seen in many people following a stroke. Apathy occurs when a person has lost motivation, becomes withdrawn, and stops doing things that used to be important to them. Apathy has a large negative impact on a person's quality of life, and can also have a large impact the people who take care of them. There are currently no FDA-approved treatments to help with apathy, and other services like therapy may be difficult to access for people who have had a stroke. To address this problem, investigators are conducting a study to find out if a form of treatment called repetitive transcranial magnetic stimulation (rTMS) can be safe and helpful for people struggling with apathy after a stroke. This study will apply a new form of rTMS which can be delivered quickly to a part of the brain called the medial prefrontal cortex (mPFC). This study will help establish whether this treatment is safe, comfortable, and effective for people with apathy after a stroke, and will help researchers develop new forms of treatment.	Accident vasculaire cérébral	Phase 1/2	Traitement symptomatique	United States	À vérifier

Essais cliniques

9

Molécule	Indication / population	Phase	NCT	Titre	Statut
MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System (Active)	Accident vasculaire cérébral	Phase 1/2	NCT07113067	Accelerated rTMS vs. Sham for Stroke Apathy	RECRUITING
Remote Transcutaneous Auricular Vagal Nerve Stimulation Paired with Task-Specific Training	Accident vasculaire cérébral	Non applicable	NCT06616831	At-Home taVNS - Stroke Rehab	COMPLETED
Accelerated intermittent theta-burst stimulation (iTBS) rTMS to right superior parietal lobule (rSPL)	Parkinson	Non applicable	NCT07701785	Superior Parietal iTBS for PD-MCI	RECRUITING
Transauricular Vagus Nerve Stimulation	SEP	Non applicable	NCT06698328	fMRI Tracking taVNS in ASD	COMPLETED
Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION)	Cancer	Phase 2	NCT07513389	Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION)	RECRUITING
Low Dose Mesenchymal Stem Cells (MSCs)	Lupus	Phase 2	NCT02633163	Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE)	COMPLETED
SLEIGH — Systemic Lupus Erythematosus in Gullah Health	Lupus	À vérifier	NCT00756769	SLEIGH — Systemic Lupus Erythematosus in Gullah Health	RECRUITING
Imaging Biomarkers of FOG Response to DBS	Parkinson	Phase 4	NCT06951906	Imaging Biomarkers of FOG Response to DBS	RECRUITING
Low Dose Mesenchymal Stem Cells (MSCs)	Lupus	Phase 1	NCT03171194	Pilot Trial of Mesenchymal Stem Cells for Systemic Lupus Erythematosus	COMPLETED

Publications

7

Molécule	Indication / population	Titre	Journal	Date
Low Dose Mesenchymal Stem Cells (MSCs)		Subconjunctival administration of allogeneic TNF-α/IL-1β licensed MSCs promotes an anti-inflammatory microenvironment in a murine model of severe alkali burn.	International immunopharmacology
SLEIGH — Systemic Lupus Erythematosus in Gullah Health		A GA microsatellite in the Fli1 promoter modulates gene expression and is associated with systemic lupus erythematosus patients without nephritis.	Arthritis research & therapy
Imaging Biomarkers of FOG Response to DBS		Regional gray matter volumes are not predictive of axial symptom response to subthalamic deep brain stimulation in Parkinsonian patients.	Parkinsonism & related disorders
Imaging Biomarkers of FOG Response to DBS		Connectivity-Based Analysis of the Stimulation Effects of Globus Pallidus Interna Deep Brain Stimulation in Parkinson's Disease: A Focus on Freezing of Gait.	Journal of movement disorders
Low Dose Mesenchymal Stem Cells (MSCs)		Kartogenin-loaded liposomes coated with alkylated hyaluronic acid for stimulated chondrogenic differentiation.	International journal of pharmaceutics
Low Dose Mesenchymal Stem Cells (MSCs)		Engineered iMSCs delivering wild-type IL-2 achieve dose-sparing tumor control via CD25-dependent CD8 T-cell activation.	BMC medicine
Low Dose Mesenchymal Stem Cells (MSCs)		Helping Underdeveloped Lungs with Cells (HULC-2): mesenchymal stromal cells in extreme preterm infants at risk of developing bronchopulmonary dysplasia - a study protocol of a phase 2 multicentre double blind randomised controlled trial in Canada.	BMJ open